[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Park SM, Shin SM, Seo HE, Kim SH, Kim HS, Park JH, Kim JH, Sohn KR: [A case of sclerosed hemangioma mimicking intrahepatic cholangiocarcinoma]. Korean J Gastroenterol; 2009 Dec;54(6):399-403
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sclerosed hemangioma mimicking intrahepatic cholangiocarcinoma].
  • Hemangioma is one of the most frequently encountered benign hepatic neoplasm which can develop secondary degeneration.
  • Its differential diagnosis is very difficult.
  • It should be included in the differential diagnosis of other hepatic lesions such as hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and metastatic hepatic tumor.
  • Abdominal ultrasonography revealed GB stone, dilated common bile duct with bile duct stone, and a 4.6 cm sized hyperechoic mass at segment 5 and 6 of the liver.
  • Abdominal dynamic computed tomography demonstrated dilated intrahepatic bile ducts and a 5 x 5 cm sized mass which showed minimally delayed enhancement.
  • We removed common bile duct stone with endoscopic retrograde cholangiopancreatography then decided to undergo right lower segmentectomy of liver due to possibility of cholangiocarcinoma.
  • [MeSH-major] Hemangioma / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Aged. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed. Ultrasonography

  • Genetic Alliance. consumer health - Hemangioma.
  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026896.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


2. Siriwardana PN, Pathirana A: Episodic biliary obstruction due to an intrahepatic biliary cystadenoma: a case report. J Med Case Rep; 2009;3:9032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Episodic biliary obstruction due to an intrahepatic biliary cystadenoma: a case report.
  • INTRODUCTION: Biliary cystadenoma is a rare, benign neoplasm of the bile ducts with malignant potential.
  • This is the fifth reported patient with an intrahepatic biliary cystadenoma giving rise to episodic biliary obstruction, which is usually caused by choledocholithiasis or periampullary carcinoma.
  • Contrast enhanced computed tomography revealed a cystic mass in segment 4B and protruding into and along the left hepatic duct.
  • Laparotomy confirmed the contrast enhanced computed tomography findings and histology revealed an intrahepatic mucinous biliary cystadenoma.
  • CONCLUSION: Biliary cystadenoma should be considered as a differential diagnosis in patients with cystic liver lesions who present with episodic biliary obstruction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2006 Sep 21;12(35):5735-8 [17007033.001]
  • [Cites] Asian J Surg. 2004 Jul;27(3):243-5 [15564171.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):833-5 [9625827.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1078-91 [7943529.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7 [12368667.001]
  • [Cites] Arch Surg. 1988 May;123(5):563-8 [3358682.001]
  • [Cites] Am J Gastroenterol. 1986 Feb;81(2):138-40 [3946368.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1434-45 [4027877.001]
  • [Cites] Clin Oncol. 1982 Jun;8(2):171-7 [7105527.001]
  • [Cites] Radiology. 1989 Apr;171(1):57-61 [2648477.001]
  • (PMID = 19918286.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2767148
  •  go-up   go-down


3. Li Q, Wang JM, Liu C, Xiao BL, Lu JX, Zou SQ: Correlation of aPKC-iota and E-cadherin expression with invasion and prognosis of cholangiocarcinoma. Hepatobiliary Pancreat Dis Int; 2008 Feb;7(1):70-5
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The abnormal expression of atypical protein kinase C-iota (aPKC-iota) subtype and E-cadherin play important roles in tumor occurrence and progression.
  • This study was designed to investigate the correlation of expression of aPKC-iota and E-cadherin with the clinicopathological characteristics and prognosis of cholangiocarcinoma, and to analyze the molecular mechanisms of invasion and metastasis of the tumor.
  • METHODS: EnVision immunohistochemistry was used to detect the expression of aPKC-iota and E-cadherin in 9 specimens of benign bile duct tissues, 35 specimens of cholangiocarcinoma and 6 specimens of metastatic cholangiocarcinoma.
  • RESULTS: The positive expression level of aPKC-iota in cholangiocarcinoma was remarkably higher than that in benign bile duct tissues (68.6% vs. 11.1%, P=0.006), but the expression level of E-cadherin was lower in cholangiocarcinoma than in benign bile duct tissues (37.1% vs. 88.9%, P=0.016).
  • Correlation analysis revealed that the expression of aPKC-iota was positively related to tumor differentiation and invasion, whereas that of E-cadherin was entirely the contrary.
  • [MeSH-major] Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / metabolism. Cadherins / metabolism. Cholangiocarcinoma / metabolism. Isoenzymes / metabolism. Protein Kinase C / metabolism
  • [MeSH-minor] Adult. Aged. Cell Polarity. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234642.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Isoenzymes; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / protein kinase C lambda
  •  go-up   go-down


Advertisement
4. Zhou JP, Dong M, Zhang Y, Kong FM, Guo KJ, Tian YL: Giant mucinous biliary cystadenoma: a case report. Hepatobiliary Pancreat Dis Int; 2007 Feb;6(1):101-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Biliary cystadenoma is a very rare cystic neoplasm of the liver.
  • Its clinical features, diagnosis, pathologic characteristics, and optimal surgical management have not been defined clearly.
  • Gross examination showed that the tumor almost occupied.
  • Pathologically, additional lobulated spaces were seen in the tumor with a lot of mucusa.
  • The interior wall was lined with bile duct tissue, indicating a benign mucinous biliary cystadenoma.
  • CONCLUSIONS: Ultrasonography and CT are the major methods for the diagnosis of mucinous biliary cystadenoma liver.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / surgery

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287176.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. Droy L, Sagan C, Paineau J, Gournay J, Mosnier JF: [Cholangiocarcinomas developing on multiple bile duct hamartomas syndrome]. Ann Pathol; 2009 Feb;29(1):24-7
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cholangiocarcinomas developing on multiple bile duct hamartomas syndrome].
  • Two cases of cholangiocarcinoma arising in a background of multiple bile duct hamartomas are reported.
  • In each case, the clinical and radiological investigations showed a liver tumor with no other concomitant disease.
  • It revealed also numerous bile duct hamartomas scattered throughout the liver.
  • In one case, some bile duct hamartomas showed a gradual morphologic transition from benign to dysplastic and neoplastic epithelium.
  • Patients with multiple bile duct hamartomas may have an increased risk of developing cholangiocarcinomas.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Hamartoma / pathology
  • [MeSH-minor] Bile Ducts, Intrahepatic / pathology. Bile Ducts, Intrahepatic / surgery. Cell Division. Disease Progression. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233090.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, Chau-in S, Thuwajit C: Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer; 2010;9:13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
  • Periostin (PN) is a multi-functional protein and has emerged as a promising marker for tumor progression.
  • Immunohistochemistry examination of a number of patients with intrahepatic CCA showed the expression of PN solely in stromal fibroblasts, but was expressed neither in cancer cells nor immune cells.
  • Low to no expression of PN was observed in tissues of benign liver disease and hepatocellular carcinoma.
  • [MeSH-major] Bile Duct Neoplasms / genetics. Bile Ducts, Intrahepatic / metabolism. Cell Adhesion Molecules / metabolism. Cholangiocarcinoma / genetics. Cholangiocarcinoma / pathology. Fibroblasts / metabolism. Gene Expression Profiling
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cell Proliferation. Disease Progression. Gene Expression Regulation, Neoplastic. Gene Knockdown Techniques. Humans. Immunohistochemistry. Integrin alpha5 / metabolism. Liver / metabolism. Liver / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Neoplasm Invasiveness. Prognosis. Proportional Hazards Models. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2008 Feb 1;68(3):918-26 [18245495.001]
  • [Cites] Mol Vis. 2007;13:2119-28 [18079685.001]
  • [Cites] Nat Rev Cancer. 2008 Jul;8(7):535-45 [18548086.001]
  • [Cites] J Histochem Cytochem. 2008 Aug;56(8):753-64 [18443362.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):1044-53 [18487994.001]
  • [Cites] Chin Med J (Engl). 2008 Jul 5;121(13):1220-5 [18710643.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2229-38 [18777559.001]
  • [Cites] Neuron. 2008 Oct 23;60(2):273-84 [18957219.001]
  • [Cites] Mol Cancer Ther. 2008 Dec;7(12):3842-51 [19056673.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3414-9 [19218429.001]
  • [Cites] Oncol Rep. 2009 Apr;21(4):957-69 [19287994.001]
  • [Cites] Sci Signal. 2009;2(77):ra32 [19567915.001]
  • [Cites] Mol Cell Neurosci. 2000 Nov;16(5):529-41 [11083916.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):843-8 [11550156.001]
  • [Cites] J Urol. 2001 Dec;166(6):2472-83 [11696814.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12182-9 [11805097.001]
  • [Cites] Neoplasma. 2001;48(6):462-7 [11949838.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11205-10 [12163646.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5358-64 [12235007.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49820-30 [12393877.001]
  • [Cites] Breast Cancer Res Treat. 2003 Feb;77(3):245-52 [12602924.001]
  • [Cites] Hepatology. 2003 May;37(5):1056-66 [12717386.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):24200-8 [12695522.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23656-65 [12716911.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):924-7 [12845951.001]
  • [Cites] J Neurochem. 2003 Aug;86(3):646-59 [12859678.001]
  • [Cites] Oncogene. 2003 Nov 20;22(52):8487-97 [14627989.001]
  • [Cites] Circulation. 2004 Feb 17;109(6):777-83 [14970115.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3992-4003 [15082792.001]
  • [Cites] Trop Med Int Health. 2004 May;9(5):588-94 [15117303.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):24498-504 [15047714.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] J Invest Dermatol. 2004 Sep;123(3):592-9 [15304102.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):943-7 [15313864.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7366-77 [15326482.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6161-5 [7541142.001]
  • [Cites] Br J Cancer. 1997;76(5):622-7 [9303361.001]
  • [Cites] Mol Biol Cell. 1999 Feb;10(2):259-70 [9950675.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1239-49 [10404027.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23349-57 [10438512.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Parasitology. 2004 Oct;129(Pt 4):455-64 [15521634.001]
  • [Cites] Oncogene. 2004 Dec 2;23(56):9042-51 [15489895.001]
  • [Cites] Int J Mol Med. 2005 Feb;15(2):253-8 [15647840.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2353-63 [15781650.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):908-15 [15731169.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7241-8 [16103075.001]
  • [Cites] Pathol Int. 2005 Nov;55(11):724-31 [16271085.001]
  • [Cites] Expert Opin Ther Targets. 2005 Dec;9(6):1217-33 [16300472.001]
  • [Cites] Semin Liver Dis. 2006 Feb;26(1):42-51 [16496232.001]
  • [Cites] J Hepatol. 2006 Jun;44(6):1066-73 [16480786.001]
  • [Cites] World J Gastroenterol. 2006 Jun 14;12(22):3585-92 [16773716.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6129-38 [16778186.001]
  • [Cites] Pathol Int. 2006 Jul;56(7):381-9 [16792547.001]
  • [Cites] Am J Trop Med Hyg. 2006 Jul;75(1):93-6 [16837714.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6928-35 [16849536.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1396-403 [17060937.001]
  • [Cites] Oncogene. 2007 Feb 22;26(8):1110-21 [17146433.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2082-94 [17043657.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1447-64 [17408641.001]
  • [Cites] J Invest Dermatol. 2007 Jun;127(6):1516-23 [17273163.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jul;110(2):273-81 [17899370.001]
  • (PMID = 20096135.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Integrin alpha5; 0 / POSTN protein, human
  • [Other-IDs] NLM/ PMC2841583
  •  go-up   go-down


7. Paik KY, Heo JS, Choi SH, Choi DW: Intraductal papillary neoplasm of the bile ducts: the clinical features and surgical outcome of 25 cases. J Surg Oncol; 2008 May 1;97(6):508-12
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary neoplasm of the bile ducts: the clinical features and surgical outcome of 25 cases.
  • BACKGROUND AND OBJECTIVES: Intraductal papillary neoplasm of the bile ducts (IPN-B) is considered an uncommon tumor.
  • Radiologically, 23 of the 25 (92.0%) showed bile duct dilatation, bile duct dilatation with or without an intraductal mass, and cystic changes of bile ducts.
  • Twenty three of the 25 patients underwent hepatic resection with or without extrahepatic bile duct resection.
  • All six patients with benign IPN-B remained alive at a mean of 26.2 postoperative months without recurrence.
  • CONCLUSIONS: A diagnosis of IPN-B is usually made in patients with biliary dilatation by radiologic study.
  • The prognosis of IPN-B, especially of the benign category, is excellent.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Carcinoma, Papillary / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Cholangiocarcinoma / secondary. Cholangiocarcinoma / surgery. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18314868.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Burgos San Juan L: [Cholangiocarcinoma]. Rev Med Chil; 2008 Feb;136(2):240-8
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholangiocarcinoma is a malignant lesion of the bile duct epithelium.
  • It is most frequently found in the confluence of the hepatic ducts, where it is called hilar cholangiocarcinoma or Klatskin tumor.
  • Its etiology is unknown but there are predisposing conditions and environmental risk factors such as primary sclerosing cholangitis, Caroli's disease, bile duct malformations, industrial toxins and parasitic infections.
  • These, in addition to laboratory exams, endoscopical and imaging procedures, lead to the diagnosis.
  • Hilar cholangiocarcinoma must be distinguished from other malignant or benign causes of biliary obstruction.
  • Cholangiocarcinoma of the distal common bile duct must be differentiated from other periampullary tumors and intrahepatic cholangiocarcinoma can be confused with a hepatocellular carcinoma.
  • The type and size of surgery depends on the location and extent of the tumor.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Cholangiocarcinoma
  • [MeSH-minor] Humans. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483680.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 43
  •  go-up   go-down


9. Kobayashi A, Takahashi S, Hasebe T, Konishi M, Nakagohri T, Gotohda N, Kinoshita T: Solitary bile duct hamartoma of the liver. Scand J Gastroenterol; 2005 Nov;40(11):1378-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary bile duct hamartoma of the liver.
  • Bile duct hamartomas, also known as von Meyenburg complexes, are benign liver malformations which usually present as multiple small nodules scattered in both lobes of the liver.
  • We report a unique case of bile duct hamartoma.
  • These findings lead us to conjecture that the lesion was a bile duct hamartoma, although its solitary nature and large size differed from those of typical bile duct hamartoma.
  • [MeSH-major] Bile Ducts, Intrahepatic / pathology. Hamartoma / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Needle. Follow-Up Studies. Hepatectomy / methods. Humans. Immunohistochemistry. Laparotomy / methods. Male. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334450.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


10. Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Yoshitomi H, Furukawa K, Mitsuhashi N, Takeuchi D, Takayashiki T, Suda K, Miyazaki M: Surgical strategy for mucin-producing bile duct tumor. J Hepatobiliary Pancreat Sci; 2010 May;17(3):236-40
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategy for mucin-producing bile duct tumor.
  • Tumors with copious mucin production within the intra- or extrahepatic bile ducts have been reported as mucin-producing bile duct tumors (MPBTs).
  • Because mucin produced by these tumors causes recurrent cholangitis and obstructive jaundice, surgical resection should be indicated even if these tumors are regarded as benign.
  • In order to choose the appropriate surgical procedure, exact preoperative assessment of tumor location and cancer extension is important, especially evaluation of the extent of superficial spreading through cholangioscopic observation and biopsy.
  • In principle, MPBTs should be resected in a manner similar to that employed for other types of bile duct carcinomas.
  • That is, major hepatectomy with or without extrahepatic bile duct resection or pancreaticoduodenectomy should be chosen as the surgical procedure, and intraoperative frozen section at the stumps of the bile duct is essential.
  • On the other hand, when precise diagnosis is completed preoperatively and the lesion is diagnosed as adenoma or carcinoma with invasion confined to the ductal wall and limited superficial spreading, limited resections preserving organ functions as much as possible can be considered as a choice among surgical procedures.
  • All ten patients with MPBT resected at our institution according to these strategies are still alive without tumor recurrence, with a median survival of 48.0 months.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Mucins / secretion
  • [MeSH-minor] Bile Ducts, Extrahepatic / metabolism. Bile Ducts, Extrahepatic / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Digestive System Surgical Procedures. Hepatectomy. Humans. Neoplasm Invasiveness. Pancreaticoduodenectomy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19649559.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 20
  •  go-up   go-down


11. Uenishi T, Yamazaki O, Tanaka H, Takemura S, Yamamoto T, Tanaka S, Nishiguchi S, Kubo S: Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol; 2008 Feb;15(2):583-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
  • This study aimed to establish the clinical significance of preoperative serum CYFRA21-1 in patients with intrahepatic cholangiocarcinoma.
  • METHODS: CYFRA21-1, carcinoembryonic antigen (CEA), and carbohydrate antigen (CA) 19-9 concentrations were measured in sera from 71 patients with intrahepatic cholangiocarcinoma.
  • RESULTS: Analysis of the areas under the receiver operator characteristic (ROC) curves clearly showed better discrimination between intrahepatic cholangiocarcinoma and benign liver diseases for CYFRA 21-1 than for CEA or CA 19-9.
  • The serum CYFRA21-1 concentration was related to tumor stage, since the CYFRA21-1 concentrations varied according to tumor size, vascular invasion, and number of tumors.
  • On multivariate analysis, a high concentration of CYFRA21-1, nodal metastases, and a microscopic resection margin involvement were independent prognostic factors associated with both tumor recurrence and postoperative death.
  • CONCLUSIONS: A high serum CYFRA21-1 concentration is associated with tumor progression and poor postoperative outcomes in patients with intrahepatic cholangiocarcinoma.
  • [MeSH-major] Antigens, Neoplasm / blood. Bile Duct Neoplasms / blood. Bile Ducts, Intrahepatic. Biomarkers, Tumor / blood. Cholangiocarcinoma / blood. Keratins / blood
  • [MeSH-minor] Aged. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Disease-Free Survival. Female. Humans. Keratin-19. Lymphatic Metastasis. Male. Multivariate Analysis. Neoplasm Invasiveness. Prognosis. ROC Curve. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17955299.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


12. Cox H, Ma M, Bridges R, Debru E, Bathe O, Sutherland F, Dixon E: Well differentiated intrahepatic cholangiocarcinoma in the setting of biliary papillomatosis: a case report and review of the literature. Can J Gastroenterol; 2005 Dec;19(12):731-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well differentiated intrahepatic cholangiocarcinoma in the setting of biliary papillomatosis: a case report and review of the literature.
  • Surprisingly, surgical pathology revealed a well-differentiated intrahepatic cholangiocarcinoma associated with biliary papillomatosis (BP).
  • BP is a rare, benign and potentially fatal disease of the intra- and extrahepatic bile ducts.
  • Although a benign disease, a review of the literature demonstrated that BP often recurs after surgical resection, carries a poor prognosis and has a moderately high malignant transformation rate.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology. Papilloma / pathology
  • [MeSH-minor] Bile Ducts / pathology. Biopsy, Needle. Cholangiopancreatography, Endoscopic Retrograde / methods. Follow-Up Studies. Humans. Immunohistochemistry. Laparotomy / methods. Male. Middle Aged. Neoplasm Staging. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16341314.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 15
  •  go-up   go-down


13. Cione GP, Cerbone D, Di Benedetto A, Podio P, Cimmino G, Parmeggiani D, Peltrini A, Lombardi V, Perrotta M: [Intrahepatic biliary cystadenoma: case report]. Suppl Tumori; 2005 May-Jun;4(3):S48-50
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intrahepatic biliary cystadenoma: case report].
  • According to the OMS classification of the epithelial benign neoplasm of the liver, the adenomas represent the most important group.
  • The biliar cistoadenoma (BCA) represents a not frequent neoplasm of the liver that has origin on the inside of the liver, and less frequently from the extrahepatic biliar system.
  • The real difficulty is represented by differential diagnosis from the other cystic lesions of the liver and by the need of its radical excision and therefore of real hepatectomy.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Cystadenoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437897.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Moon CM, Bang S, Chung JB, Park SW, Song SY, Yun M, Lee JD: Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol; 2008 May;23(5):759-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.
  • BACKGROUND AND AIM: (18)F-Fluoro-2-deoxy-d-glucose positron emission tomography ((18)FDG-PET) is promising for diagnosis and treatment of various malignancies.
  • The aim of this study was to evaluate the clinical usefulness of (18)FDG-PET in differential diagnosis and staging of cholangiocarcinomas according to the intrahepatic, perihilar and common bile duct lesions and to compare with computerized tomography (CT) scan.
  • RESULTS: The overall accuracy of (18)FDG-PET for discriminating malignant diseases of bile duct from benign conditions was slightly higher than that of CT scan (88.9% vs 81.5%).
  • The sensitivity of (18)FDG-PET in perihilar cholangiocarcinoma was lower than the value of intrahepatic and common bile duct cancers (83.3% vs 91.3%, 90.9%); moreover, in cases of perihilar cancer, the sensitivity of (18)FDG-PET was lower than that of CT scans (83.3% vs 91.7%). (18)FDG-PET detected nine distant metastatic lesions not found by other imaging studies and excluded two patients who potentially had resectable condition in other imaging studies from unnecessary laparotomy.
  • CONCLUSION: The clinical usefulness of (18)FDG-PET in differential diagnosis of bile duct cancers is related to the site of primary disease.
  • Although it is a helpful method for differential diagnosis especially in cases of intrahepatic and common bile duct cancers, (18)FDG-PET can not provide confirmative clues in perihilar cholangiocarcinoma. (18)FDG-PET may hold promise in the detection of hidden distant metastasis and can play an additional role in the evaluation of resectability. (18)FDG-PET can be complementary to CT scan in diagnosing and staging of cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / radionuclide imaging. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology. Cholangiocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931372.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


15. Li Q, Wang JM, Liu C, Xiao BL, Su Y, Zou SQ: [Expression and significance of aPKC-iota and E-cadherin in cholangiocarcinoma]. Ai Zheng; 2007 Jul;26(7):715-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Studies showed that the abnormal expression of atypical protein kinase C iota subtype (aPKC-iota) and E-cadherin plays an important role in tumor genesis and progression.
  • METHODS: The expression of aPKC-iota and E-cadherin in 9 specimens of benign bile duct tissues and 35 specimens of cholangiocarcinoma was detected by EnVision immunohistochemistry, and their correlations to the clinicopathologic characteristics and invasion of cholangiocarcinoma were analyzed.
  • RESULTS: The positive rate of aPKC-iota was significantly higher in cholangiocarcinoma than in benign bile duct tissues (68.6% vs. 11.1%, P = 0.006), while the positive rate of E-cadherin was significantly lower in cholangiocarcinoma than in benign bile duct tissues (37.1% vs. 88.9%, P = 0.016).
  • [MeSH-major] Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic. Cadherins / metabolism. Cholangiocarcinoma / metabolism. Isoenzymes / metabolism. Protein Kinase C / metabolism
  • [MeSH-minor] Adult. Aged. Bile Ducts / metabolism. Cell Differentiation. Cholangitis / metabolism. Choledochal Cyst / metabolism. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626746.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Isoenzymes; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / protein kinase C lambda
  •  go-up   go-down


16. Wang WB, Li YH, Liu B, Wang HS, Cui AR, Zhnag XH: [Correlation between PPARgamma and VEGF-C expression in extrahepatic cholangioadenocarcinoma (EHCAC) and their prognostic significance]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):773-7
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expressions of PPARgamma and VEGF-C were detected by immunohistochemistry in 69 cases of EHCAC, 12 cases of non-tumor bile duct epithelium, and their relationship to clinicopathological parameters and follow-up were analyzed.
  • RESULTS: The positive rate of PPARgamma expression in 69 cases of EHCAC was 59.4%, significantly higher than that in 12 cases of non-tumor bile duct epithelium (0%), (P < 0.01).
  • The positive rate of VEGF-C in 69 cases of EHCAC was 84.1%, also significantly higher than 16.7% in 12 cases of benign bile duct epithelium (P < 0.05).
  • [MeSH-major] Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic. Cholangiocarcinoma / metabolism. PPAR gamma / metabolism. Vascular Endothelial Growth Factor C / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021832.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / PPAR gamma; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


17. Hohmann J, Loddenkemper C, Albrecht T: Assessment of a biliary hamartoma with contrast-enhanced sonography using two different contrast agents. Ultraschall Med; 2009 Apr;30(2):185-8
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low-MI contrast-enhanced ultrasound (CEUS) with SonoVue (Bracco, Milano, Italy) showed an enhancement pattern which was typical for benign liver lesions while high-MI CEUS with Levovist (Schering, Berlin, Germany) revealed a contrast defect in the liver late phase (4:30 min p. i.) which is typical for a malignant lesion.
  • Histology showed a benign biliary hamartoma and incomplete cirrhosis.
  • Nevertheless biliary duct adenomas are benign lesions with almost the same perfusion properties as normal liver parenchyma.
  • [MeSH-major] Adenoma, Bile Duct / ultrasonography. Bile Duct Diseases / ultrasonography. Bile Duct Neoplasms / ultrasonography. Bile Ducts, Intrahepatic / ultrasonography. Contrast Media. Hamartoma / ultrasonography. Phospholipids. Polysaccharides. Sulfur Hexafluoride. Ultrasonography, Doppler, Duplex
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Esophageal Neoplasms / pathology. Esophageal Neoplasms / ultrasonography. Humans. Incidental Findings. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Male. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726842.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / Polysaccharides; 0 / contrast agent BR1; 127279-08-7 / SHU 508; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


18. Somorácz A, Tátrai P, Horváth G, Kiss A, Kupcsulik P, Kovalszky I, Schaff Z: Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Hum Pathol; 2010 Sep;41(9):1310-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we proved the utility of agrin immumohistochemistry in discriminating between HCCs and benign parenchymal lesions.
  • Immunohistochemistry for agrin was performed on 25 HCC, 16 intrahepatic CCC, 20 colorectal cancer metastasis (CRCm), and 18 pancreatic ductal carcinoma metastasis (PDCm) samples and evaluated with both quantitative and qualitative methods.
  • Regardless of tumor grade, agrin immunostaining was strong in the microvessels of HCCs.
  • As opposed to HCC, agrin immunostaining was faint or nearly absent from the CD34-positive microvessels of CCC, CRCm, and PDCm; rather, it was detected in the basement membranes surrounding tumor cell pseudoglandules.
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Bile Duct Neoplasms / genetics. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / secondary. Cholangiocarcinoma / genetics. Cholangiocarcinoma / metabolism. Cholangiocarcinoma / pathology. DNA, Neoplasm / analysis. Diagnosis, Differential. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Female. Gene Expression Regulation, Neoplastic. Hepatectomy. Humans. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471664.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Agrin; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Messenger
  •  go-up   go-down


19. Popescu I, Ciurea S, Romanescu D, Boros M: Isolated resection of the caudate lobe: indications, technique and results. Hepatogastroenterology; 2008 May-Jun;55(84):831-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: This paper reports a series of 24 isolated caudate lobe resections (ICLR), performed for 13 benign tumors (10 hemangiomas, 2 focal nodular hyperplasias, 1 adenoma) and 11 malignant tumors (3 hepatocarcinomas, 1 peripheral cholangiocarcinoma and 7 metastatic - 5 colorectal carcinomas, 1 breast carcinoma, 1 adrenal carcinoma).
  • RESULTS: Complications occurred in 7 cases (3 bile leaks, 3 abdominal fluid collections and one liver failure leading to death).
  • From the 10 patients with malignant tumors who survived the operation, 7 developed recurrences: 2 intrahepatic, 1 retroperitoneal, 4 systemic.
  • [MeSH-minor] Adenoma, Liver Cell / mortality. Adenoma, Liver Cell / pathology. Adenoma, Liver Cell / surgery. Adrenal Gland Neoplasms / mortality. Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Adult. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Breast Neoplasms / mortality. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Female. Focal Nodular Hyperplasia / mortality. Focal Nodular Hyperplasia / pathology. Focal Nodular Hyperplasia / surgery. Hemangioma / mortality. Hemangioma / pathology. Hemangioma / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Postoperative Complications / mortality. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705277.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


20. Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, Kongtawelert P: Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol; 2010 Jan;25(1):129-37
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Six groups were studied which included 40 healthy subjects, 50 patients with chronic hepatitis (CH), 50 patients with liver cirrhosis (LC), 100 patients with HCC, 50 patients with intrahepatic cholangiocarcinoma (ICC) and 50 patients with metastatic carcinoma (MCA).
  • Detectable GPC3 was significantly correlated with the presence of viral hepatitis markers but was not correlated with tumor size and stage of HCC.
  • The combined use of serum GPC3 and AFP provides a potentially promising tool to better differentiate HCC from benign liver disorders, as well as from other liver cancers.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / blood. Glypicans / blood. Liver Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / blood. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / blood. Cholangiocarcinoma / diagnosis. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Hepatitis, Chronic / blood. Hepatitis, Chronic / diagnosis. Humans. Liver Cirrhosis / blood. Liver Cirrhosis / diagnosis. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. ROC Curve. Sensitivity and Specificity. Up-Regulation. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793164.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans; 0 / alpha-Fetoproteins
  •  go-up   go-down


21. Lang H, Broelsch CE: [Liver resection and transplantation for hepatic tumors]. Internist (Berl); 2007 Jan;48(1):30-9
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This work provides an overview of the current status of surgical therapy for the most frequent, benign liver tumours, as well as for hepatocellular and cholangiocellular carcinoma.
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / pathology. Adenoma, Liver Cell / surgery. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / pathology. Focal Nodular Hyperplasia / surgery. Hemangioma / diagnosis. Hemangioma / pathology. Hemangioma / surgery. Humans. Liver / pathology. Neoplasm Staging. Tissue and Organ Procurement. Tomography, X-Ray Computed. Ultrasonography

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1997 Nov-Dec;21(9):983-90; discussion 990-1 [9361515.001]
  • [Cites] HPB Surg. 1997;10 (3):159-62 [9174860.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):183-9 [12620915.001]
  • [Cites] Liver Int. 2006 May;26(4):433-8 [16629646.001]
  • [Cites] J Am Coll Surg. 2005 Nov;201(5):663-70 [16256907.001]
  • [Cites] Liver Transpl. 2005 Jul;11(7):767-75 [15973710.001]
  • [Cites] Hepatology. 1999 Jan;29(1):62-7 [9862851.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):229-35 [16432356.001]
  • [Cites] Hepatology. 2001 May;33(5):1080-6 [11343235.001]
  • [Cites] Hepatology. 1988 May-Jun;8(3):531-7 [2453430.001]
  • [Cites] Liver Transpl. 2001 Oct;7(10):877-83 [11679986.001]
  • [Cites] World J Surg. 1995 Nov-Dec;19(6):807-13 [8553670.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1394-403 [11391528.001]
  • [Cites] Liver Transpl. 2006 Aug;12(8):1260-7 [16826556.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3654-60 [15897561.001]
  • [Cites] Arch Surg. 2004 Mar;139(3):320-5; discussion 326 [15006892.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):134-43 [15622001.001]
  • [Cites] Hepatology. 2005 May;41(5):1130-7 [15841454.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):282-90 [10472929.001]
  • [Cites] Surgery. 2002 Mar;131(3):311-7 [11894036.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):479-90 [9790338.001]
  • [Cites] Ann Surg. 2001 May;233(5):652-9 [11323504.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):451-9; discussion 459-61 [15319716.001]
  • [Cites] Arch Surg. 2001 May;136(5):528-35 [11343543.001]
  • [Cites] Liver Transpl. 2006 Jun;12(6):934-40 [16528715.001]
  • [Cites] Chirurg. 2006 Jan;77(1):53-60 [16170505.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1182-7 [10971425.001]
  • [Cites] J Pathol. 2001 Apr;193(4):476-82 [11276006.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):429-36 [9358085.001]
  • [Cites] Transplant Proc. 1999 Feb-Mar;31(1-2):500-1 [10083209.001]
  • [Cites] Liver Transpl. 2005 Oct;11(10):1265-72 [16184545.001]
  • [Cites] J Am Coll Surg. 2005 Nov;201(5):656-62 [16256906.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):885-92; discussion 892-3 [14631225.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):324-31 [10458250.001]
  • [Cites] Liver Transpl Surg. 1999 Mar;5(2):91-5 [10071346.001]
  • [Cites] Arch Surg. 2005 Jul;140(7):629-38; discussion 638 [16027326.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):35-41 [7740808.001]
  • [Cites] World J Surg. 2003 Apr;27(4):443-7 [12658490.001]
  • [Cites] Transplantation. 2005 Feb 27;79(4):483-7 [15729176.001]
  • [Cites] Arch Surg. 1995 Feb;130(2):153-6 [7848084.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1331-8 [16475212.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):315-21; discussion 321-3 [14501497.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):122-6 [7881929.001]
  • [Cites] Surgery. 2000 May;127(5):498-505 [10819057.001]
  • [Cites] Liver Transpl. 2004 Mar;10(3):440-7 [15004774.001]
  • [Cites] Pathologe. 2006 Jul;27(4):238-43 [16736176.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):311-6 [11995440.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1068-70 [9717998.001]
  • [Cites] Lancet. 1990 Nov 10;336(8724):1150-3 [1978027.001]
  • [Cites] J Am Coll Surg. 2001 Oct;193(4):384-91 [11584966.001]
  • (PMID = 17195060.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 58
  •  go-up   go-down


22. Liu L, Wang J, Liu B, Dai S, Wang X, Chen J, Huang L, Xiao X, He D: Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. J Cell Biochem; 2008 Jun 1;104(3):745-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cholangiocarcinoma (CC) is devastating neoplasm and very few specific biomarkers could be used in clinical diagnosis.
  • ELISA assay indicated that TTR levels were consistent with SELDI analysis in CC compared with healthy control and benign diseases of hepatobiliary (P < 0.001).
  • TTR combining with CA19-9 to differentiate CC from benign hepatobiliary diseases showed sensitivity and specificity were 98.2% and 100%, respectively.
  • CONCLUSION: The levels of TTR were significantly down-regulated in sera of CC patients and may be complementary markers of CA19-9 in diagnosis for CC.
  • [MeSH-major] Bile Duct Neoplasms / blood. Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / metabolism. Cholangiocarcinoma / blood. Cholangiocarcinoma / metabolism. Gene Expression Regulation, Neoplastic. Prealbumin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. CA-19-9 Antigen / biosynthesis. Case-Control Studies. Female. Humans. Male. Middle Aged


23. Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, Cymes K, DeMatteo RP, D'Angelica M, Blumgart LH, Singh B: Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol; 2006 Mar 1;24(7):1152-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue microarrays were prepared from paraffin-embedded surgical specimens with triplicate cores of BTA and benign tissue.
  • Tumor sites of origin were intrahepatic cholangiocarcinoma (IH; n = 23), hilar cholangiocarcinoma (Hilar; n = 54), gallbladder (GB; n = 32), and distal bile duct (Distal; n = 19).
  • CONCLUSION: BTAs differentially express cell cycle-regulatory proteins based on tumor location and morphology.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Biomarkers, Tumor / analysis. Cell Cycle Proteins / analysis. Cholangiocarcinoma / pathology. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Aged. Cyclin D1 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Proliferating Cell Nuclear Antigen / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-mdm2 / analysis. Survival Analysis. Tumor Suppressor Protein p53 / analysis. Up-Regulation

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505435.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / p27 antigen; 136601-57-5 / Cyclin D1; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


24. Lazaridis KN, Gores GJ: Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis; 2006 Feb;26(1):42-51
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The major challenges of CCA in PSC patients relate to lack of methods for early diagnosis and the absence of effective treatment.
  • Early diagnosis of CCA in PSC is delayed because its clinical presentation can mimic benign dominant biliary strictures.
  • Only then will chemoprevention, early diagnosis, and therapy of CCA in patients with PSC improve.
  • [MeSH-major] Bile Duct Neoplasms / complications. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / complications. Cholangitis, Sclerosing / complications
  • [MeSH-minor] Epidemiologic Studies. Humans. Incidence. Neoplasm Staging. Precancerous Conditions. Risk Factors

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16496232.001).
  • [ISSN] 0272-8087
  • [Journal-full-title] Seminars in liver disease
  • [ISO-abbreviation] Semin. Liver Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


25. Leelawat K, Leelawat S, Ratanachu-Ek T, Trubwongchareon S, Wannaprasert J, Tripongkaruna S, Chantawibul S, Tepaksorn P: Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients. World J Gastroenterol; 2006 Jul 14;12(26):4195-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients.
  • METHODS: The serum of thirty three cholangiocarcinoma patients, forty one benign biliary tract disease patients and ten healthy volunteers were collected and analyzed for the expression of hTERT mRNA by real-time reverse transcriptase-polymerase chain reaction (RT-PCR).
  • RESULTS: hTERT mRNA was detected in 28 of 33 (84.85%) of serum obtained from cholangiocarcinoma patients and 9 of 41 (21.9%) of serum obtained from benign biliary tract disease patients. hTERT mRNA was not detected in any serum obtained from healthy volunteers. on the other hand the common tumor marker, CA19-9 was detected in 20 of 33 (60.6%) of serum obtained from cholangiocarcinoma patients and 8 of 41 (19.5%) of serum obtained from benign biliary tract disease patients.
  • However, no correlation was found between the present of serum hTERT mRNA and tumor staging.
  • It offers a novel tumor marker, which can be used as a complementary study for diagnosis of cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / blood. Biomarkers, Tumor / blood. Cholangiocarcinoma / blood. DNA-Binding Proteins / genetics. RNA, Messenger / blood. Telomerase / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Ducts, Intrahepatic. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Jan-Feb;7(1):55-66 [10674450.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3823-6 [11051224.001]
  • [Cites] Nucleic Acids Res. 2001 Aug 15;29(16):3385-93 [11504876.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:179-88 [11708476.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1186-93 [12142371.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Nov;5(6):907-16 [16255632.001]
  • [Cites] Oncology. 2004;66(3):167-79 [15218306.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3166-70 [10397260.001]
  • [Cites] Acta Otolaryngol. 2005 Apr;125(4):409-14 [15823813.001]
  • [Cites] Nat Rev Genet. 2005 Aug;6(8):611-22 [16136653.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Jul-Sep;6(3):276-81 [16235986.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):245-52 [14654933.001]
  • (PMID = 16830373.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC4087372
  •  go-up   go-down






Advertisement